{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T14:52:01Z","timestamp":1790261521248,"version":"4.1.0"},"reference-count":35,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,9,6]],"date-time":"2012-09-06T00:00:00Z","timestamp":1346889600000},"content-version":"vor","delay-in-days":3080,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Obesity Research"],"published-print":{"date-parts":[[2004,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:italic>Objective<\/jats:italic>: Several randomized, placebo\u2010controlled, double\u2010blind trials in insulin\u2010treated patients with type 2 diabetes have shown that adjunctive therapy with pramlintide reduces hemoglobin (Hb)A<jats:sub>1c<\/jats:sub> with concomitant weight loss. This analysis further characterizes the weight\u2010lowering effect of pramlintide in this patient population.<\/jats:p><jats:p><jats:italic>Research Methods and Procedures<\/jats:italic>: This pooled post hoc analysis of two long\u2010term trials included all patients who were overweight\/obese at baseline (BMI &gt; 25 kg\/m<jats:sup>2<\/jats:sup>), and who were treated with either 120 \u03bcg pramlintide BID (<jats:italic>n<\/jats:italic> = 254; HbA<jats:sub>1c<\/jats:sub> 9.2%; weight, 96.1 kg) or placebo (<jats:italic>n<\/jats:italic> = 244; HbA<jats:sub>1c<\/jats:sub> 9.4%; weight, 95.0 kg). Statistical endpoints included changes from baseline to week 26 in HbA<jats:sub>1c<\/jats:sub>, body weight, and insulin use.<\/jats:p><jats:p><jats:italic>Results<\/jats:italic>: Pramlintide treatment resulted in significant reductions from baseline to week 26, compared with placebo, in HbA<jats:sub>1c<\/jats:sub> and body weight (both, <jats:italic>p<\/jats:italic> &lt; 0.0001), for placebo\u2010corrected reductions of \u22120.41% and \u22121.8 kg, respectively. Approximately three times the number of patients using pramlintide experienced a \u22655% reduction of body weight than with placebo (9% vs. 3%, <jats:italic>p<\/jats:italic> = 0.0005). Patients using pramlintide also experienced a proportionate decrease in total daily insulin use (<jats:italic>r<\/jats:italic> = 0.39, <jats:italic>p<\/jats:italic> &lt; 0.0001). The greatest placebo\u2010corrected reductions in weight at week 26 were observed in pramlintide\u2010treated patients with a BMI &gt;40 kg\/m<jats:sup>2<\/jats:sup> and in those concomitantly treated with metformin (both, <jats:italic>p<\/jats:italic> &lt; 0.001), for placebo\u2010corrected reductions of \u22123.2 kg and \u22122.5 kg, respectively.<\/jats:p><jats:p><jats:italic>Discussion<\/jats:italic>: These findings support further evaluation of the weight\u2010lowering potential of pramlintide in obese patients with type 2 diabetes.<\/jats:p>","DOI":"10.1038\/oby.2004.76","type":"journal-article","created":{"date-parts":[[2008,4,21]],"date-time":"2008-04-21T09:07:37Z","timestamp":1208768857000},"page":"661-668","source":"Crossref","is-referenced-by-count":162,"title":["Effect of Pramlintide on Weight in Overweight and Obese Insulin\u2010Treated Type 2 Diabetes Patients"],"prefix":"10.1002","volume":"12","author":[{"given":"Priscilla","family":"Hollander","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David G.","family":"Maggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Ruggles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Fineman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Larry","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orville G.","family":"Kolterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Weyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,9,6]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.2165\/00024677-200302010-00004"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-051X.1988.tb01003.x"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1002\/9780470757109.ch7"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.1.21"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.17.10.1100"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.23.11.1660"},{"key":"e_1_2_7_8_2","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1210\/jcem.86.1.7157","article-title":"The Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes","volume":"86","author":"Lebovitz H. E.","year":"2001","journal-title":"J Clin Endocrinol Metab."},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-131-3-199908030-00004"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.12.6.379"},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.20.11.1744"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.2174\/1381612013397357"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00060793-199708000-00006"},{"key":"e_1_2_7_14_2","first-page":"493","article-title":"High affinity amylin binding sites in rat brain","volume":"44","author":"Beaumont K.","year":"1993","journal-title":"Mol Pharmacol."},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/0306-4522(94)90388-3"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(97)90170-0"},{"key":"e_1_2_7_17_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF00401833"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1038\/oby.2002.147"},{"issue":"1","key":"e_1_2_7_19_2","first-page":"A302","article-title":"Comparison of central and peripheral administration of amylin on reduction of food intake in rats","volume":"40","author":"Bhavsar S.","year":"1997","journal-title":"Diabetologia."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.141.2.7378"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2007-978590"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0801664"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.11.8593"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0026-0495(99)90232-9"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150260007390"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.2337\/diaclin.20.3.137"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1089\/15209150252924094"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.3.784"},{"issue":"1","key":"e_1_2_7_29_2","first-page":"A232","article-title":"Pramlintide therapy in addition to insulin in type 2 diabetes: effect on metabolic control after 6 months","volume":"42","author":"Gottlieb A.","year":"1999","journal-title":"Diabetologia."},{"key":"e_1_2_7_30_2","volume-title":"Physical Status: The Use and Interpretation of Anthropometry.","author":"World Health Organization Expert Committee","year":"1995"},{"key":"e_1_2_7_31_2","volume-title":"Managing the Global Epidemic of Obesity. Report of the WHO Consultation of Obesity.","author":"International Obesity Task Force","year":"1997"},{"key":"e_1_2_7_32_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.16.1.193"},{"key":"e_1_2_7_33_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.21.8.1288"},{"key":"e_1_2_7_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-1326.2000.00071.x"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1055\/s-2002-34790"},{"key":"e_1_2_7_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2982.2002.00311.x"}],"container-title":["Obesity Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1038%2Foby.2004.76","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1038\/oby.2004.76","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T08:10:26Z","timestamp":1698739826000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1038\/oby.2004.76"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,4]]},"references-count":35,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2004,4]]}},"alternative-id":["10.1038\/oby.2004.76"],"URL":"https:\/\/doi.org\/10.1038\/oby.2004.76","archive":["Portico"],"relation":{},"ISSN":["1071-7323","1550-8528"],"issn-type":[{"value":"1071-7323","type":"print"},{"value":"1550-8528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,4]]}}}